Rhelixa, Inc. and Ryu Nakaki will deliver the keynote lecture, "Epigenome Analysis Opens a New Era of Personalized Anti-Aging" on March 6, 2026, from 13:30 to 13:50.

Liberace, Inc. will be held in March 2026.Hyper Interdisciplinary Conference Tokyo 2026(Head Office: Chuo-ku, Tokyo; hereinafter "Rhelixa") as a keynote speaker.

Mr. Nakaki said,Focusing on epigenomics since the beginning of his graduate research, he founded Rhelixa in 2015. Rhelixa is developing support services for omics research based on its unique epigenome analysis technology, and continues to take on the challenge of delivering scientific knowledge of epigenomics to society in a variety of forms, from support for basic research to medical and social implementation.

In his presentation, Rhelixa will provideEpiClock" biological age measurement test®"The presentation will introduce the research background, technology, and scientific credibility of the "Mere Old Man" and its social implementation through co-creation with medical care, government, and business, and will discuss "the age when individual aging can be quantified.

Rhelixa was founded in 2015 based on the technological potential of "epigenome analysis," which was the research theme of founder Mr. Nakaki during his graduate school days. From the very beginning of the company's foundation, its approach to social implementation based on a deep understanding of the technology by scientists themselves resonates deeply with the philosophy of REVANES, which is "to realize the development of science and technology and to contribute to the global community.

In 2024, the epigenome Facing Aging and Life Improvement through a New Approach of Measuring Ageepic clock®Co-launched theEpiClock®We have continuously cooperated as an operating partner in co-creation projects, building contacts with medical institutions, food companies, and others together to help accelerate social implementation.

Rhelixa has been continuously developing its contract analysis business for universities and research institutions since 2015, and to date has conducted a cumulative total of approximately 13,000 support projects for 572 private companies and 368 universities and other research institutions (including approximately 700 support projects related to epigenome analysis)[1 ]. Our analysis technologies have been used in papers and reports by universities, medical institutions, and researchers in Japan and abroad[2], and we have a high degree of reliability, a proven track record, and an established reputation for our analysis technologies.

EpiClock® is a model for predicting biological age (epigenetic clock) designed specifically for the characteristics of the Japanese population. Its development uses Rhelixa's proprietary transfer learning method called Transfer Elastic Net (TENet) [3]. This method enables the construction of highly accurate models that reflect the epigenomic (DNA methylation) patterns of the Japanese population. The EpiClock® models constructed with this method have been established as models with high suitability and utility for the Japanese population, with the prediction error (RMSE) for biological age for the Japanese population reduced by approximately 17-661 TP3T and the correlation coefficient (PCC) increased by +0.012 to +0.026 points for all models compared to representative models developed overseas [4]. The PCC (correlation coefficient) increased by +0.012 to +0.026 points for all models, establishing it as a model with high suitability and utility for Japanese [5].

As of August 2025, epic clock®has been introduced in approximately 140 medical institutions and clinics nationwide. In addition, 27 companies from a wide range of industries, including food, housing, and pharmaceuticals, are participating as co-creation partners in EpiClock®A "co-creation project" is also underway [6], from which seven projects are underway.

Several joint research projects with universities and research institutions are in progress, including a joint research project with Kyoto Prefectural University of Medicine. In these joint studies, EpiClock® is being used to "visualize aging" in an attempt to scientifically evaluate the aging of Japanese people and to narrow down lifestyle habits and factors that are key to healthy longevity [7].

Through these clinical and community partnerships, EpiClock® is developing into a technology that is "trusted and used" both scientifically and socially.

This keynote speech is positioned as the culmination of the "co-creation journey" between Rhelixa, which has continued to take on the challenge of connecting science and society, and LIVERNESS, which has supported it.

Keynote Speech Summary

Conference Name: Japan Society for Hyperdifferent Fields Tokyo 2026
Website:https://hic.lne.st/schedule/tokyo2026/
Speaker: Mr. Ryu Nakaki (President, Rhelixa Corporation)
Title: Epigenome Analysis Opens a New Era of Personal Anti-Aging
Date: Friday, March 6, 2026
Venue: Bellesalle Shinjuku Grand Conference Center
(Sumitomo Fudosan Shinjuku Grand Tower 5F, 8-17-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo)
Organized by: Liverness Co.

Notes and reference links

[1] Available on the company's website https://www.rhelixa.com/service/
[2] 107 peer-reviewed papers published through 2024 (including 13 co-authored papers, 77 in Materials & Methods, and 17 in Acknowledgements)
[3] Patent pending: Patent Application 2024-074544, see company website for an overview of the model structure.
[4] Horvath. Genome Biol. 2013. Hannum. Mol Cell. 2013.Levine. Aging (Albany NY). 2018.
[5] Transfer Elastic Net for Developing Epigenetic Clocks for the Japanese Population Tomo & Nakaki. Mathematics. 2024.
[6] Available on the company's website https://epiclock.jp/co-creation/
[7] Available on the company's website https://www.rhelixa.com/newsrelease-20251017/

 

About Rhelixa Corporation

Company name: Rhelixa Inc.https://www.rhelixa.com/)
Headquarters: KDX Ginza East Building 5F, 3-7-2 Irifune, Chuo-ku, Tokyo 104-0042, Japan
Established: February 2015
Representative Director: Ryu Nakaki
Capital: 589 million yen (including capital reserve)
Number of employees: 47 (including 15 Ph.)
Business activities: Contract omics analysis and consulting services, development and operation of cloud services to support medical biology research, and provision of research, development and services related to anti-aging.

Registration for auditing and participation is now open.

We look forward to welcoming many people from academia, venture companies, large corporations, local medium-sized and small companies, local factories, producers, local governments, junior high and high school students, and technical college students to the Hyperdifferent Field Conference.